Mice challenged with B16‐OVA or B16F10 melanoma cells showed improved survival, tumour control and regression, as well as increased frequencies of tumour‐specific CD8+ effector T cells, when immunised with ACM‐encapsulated tumour‐antigen‐peptides. Here, CD8A is linked to melanoma.